Cover Image

RANOLAZINE IN ISCHEMIC HEART DISEASE

Show other versions (1)

<p>Study results of a new anti-anginal drug (an inhibitor of sodium channels - ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.</p>

Saved in:

Bibliographic Details
Main Author:	V. P. Lupanov (Author)
Format:	Book
Published:	Столичная издательская компания, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RANOLAZINE IN ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015)

Mechanical effects of ranolazine on normal and diabetic-isolated rat heart
by: Hajar Khazraei, et al.
Published: (2021)

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy
by: James A. Coleman, et al.
Published: (2024)

Emerging clinical role of ranolazine in the management of angina
by: David S Vadnais, et al.
Published: (2010)

Proton Dependent Inhibition of the Cardiac Sodium Channel Nav1.5 by Ranolazine
by: Stanislav eSokolov, et al.
Published: (2013)

Ischemic Heart Disease
Published: (2013)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Published: (2015)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Published: (2015)

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)
Published: (2015)

Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study
by: Shammas NW, et al.
Published: (2015)

Antiarrhythmic Properties of Ranolazine: Inhibition of Atrial Fibrillation Associated TASK-1 Potassium Channels
by: Antonius Ratte, et al.
Published: (2019)

Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation
by: Julian Wolfes, et al.
Published: (2020)

Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations
by: Aziz Unnisa, et al.
Published: (2023)

Noise and ischemic heart disease
by: Jens Peter Bonde, et al.
Published: (2012)

ENDOTHELIAL DYSFUNCTION IN ISCHEMIC HEART DISEASE
by: N. E. Zakirova, et al.
Published: (2016)

Novel Strategies in Ischemic Heart Disease
Published: (2012)

The role of irisin in ischemic heart disease
by: Patrycja Agata Piątek, et al.
Published: (2019)

The role of irisin in ischemic heart disease
by: Patrycja Agata Piątek, et al.
Published: (2019)

MYOCARDIAL REMODELING IN ISCHEMIC HEART DISEASE
by: A. N. Zakirova, et al.
Published: (2016)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
by: F. I. Belyalov
Published: (2017)

MYOCARDIAL REMODELING IN ISCHEMIC HEART DISEASE
by: A. N. Zakirova, et al.
Published: (2016)

Familial Aggregation for Ischemic Heart Disease
by: José Leandro Pérez Guerrero, et al.
Published: (2022)

Curbing Inflammation in the Ischemic Heart Disease
by: Paulo Roberto B. Evora, et al.
Published: (2013)

RAMIPRIL EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION AND ISCHEMIC HEART DISEASE
by: A. I. Chesnikova, et al.
Published: (2016)

Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning
by: Sarah Rouhana, et al.
Published: (2021)

COMORBIDITIES IN PATIENTS WITH ISCHEMIC HEART DISEASE: GENDER DIFFERENCES
by: A. N. Sumin, et al.
Published: (2017)

The Clinical Outcome Comparison of Ischemic Stroke with and without Ischemic Heart Disease
by: Rizaldy Taslim Pinzon, et al.
Published: (2018)

NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY
by: S. N. Tereschenko, et al.
Published: (2015)

NITRATES IN ISCHEMIC HEART DISEASE TREATMENT, YESTERDAY AND TODAY
by: S. N. Tereschenko, et al.
Published: (2015)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015)

THE POSSIBILITY OF USAGE OF METABOLIC CORRECTION THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND HEART FAILURE
by: I. V. Sergienko, et al.
Published: (2015)

THE POSSIBILITY OF USAGE OF METABOLIC CORRECTION THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND HEART FAILURE
by: I. V. Sergienko, et al.
Published: (2015)

IMMUNO-INFLAMATORY RESPONSE IN ISCHEMIC HEART DISEASE
by: N. E. Zakirova, et al.
Published: (2015)

IMMUNO-INFLAMATORY RESPONSE IN ISCHEMIC HEART DISEASE
by: N. E. Zakirova, et al.
Published: (2015)

Ischemic heart disease in Cuba. An update. 2015.
by: Nurys Armas Rojas Armas Rojas, et al.
Published: (2015)

Ischemic Heart Disease in the Context of Different Comorbidities
Published: (2022)

Health behavior of patients with ischemic heart disease
by: Paweł Węgorowski, et al.
Published: (2017)